Therapeutic strategies aimed at restoring YTHDF1 function or reducing TSC22D1 expression may suppress tumor growth, particularly in EBV-associated gastric cancer (EBVaGC), which currently lacks targeted therapies. This evidence concerns the gene TSC22D1 and neoplasm.